EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) play an important role in the treatment of non-small cell lung cancer (NSCLC), especially in the first line setting where both the objective response rate and progression-free survival (PFS) are better than chemotherapy once the cancer bears the mutant EGFR [1–3].